Galectin-3 (Gal-3), a β-galactoside-binding lectin, has been implicated in myocardial fibrosis, development of left ventricular (LV) dysfunction and transition from compensated left ventricular (LV) hypertrophy to overt heart failure (HF) in various experimental HF models [1,2,3,4]. The gene discussed is LGALS3; the disease is Myocardial fibrosis.